Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response. - Fischetti I; Botti L; Sulsenti R; Cancila V; Enriquez C; Ferri R; Bregni M; Crivelli F; Tripodo C; Colombo MP; Jachetti E (Epigenomics, 2024)